Case Reports in Hematology (Jan 2019)

An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review

  • Reina Takeda,
  • Kazuaki Yokoyama,
  • Seiichiro Kobayashi,
  • Toyotaka Kawamata,
  • Sousuke Nakamura,
  • Tomofusa Fukuyama,
  • Mika Ito,
  • Nozomi Yusa,
  • Eigo Shimizu,
  • Nobuhiro Ohno,
  • Rui Yamaguchi,
  • Seiya Imoto,
  • Satoru Miyano,
  • Kaoru Uchimaru,
  • Arinobu Tojo

DOI
https://doi.org/10.1155/2019/4532434
Journal volume & issue
Vol. 2019

Abstract

Read online

Therapy-related myeloid neoplasm (t-MN) is a late and lethal complication induced by chemotherapy and/or radiation therapy. Hematological malignancy is one of the most common primary diseases in patients with t-MN. However, the occurrence of t-MN in adult T-cell leukemia/lymphoma (ATL) patients is rarely reported, possibly due to the dismal prognosis of ATL per se. Here, we report a 62-year-old female who developed t-MN only three months after the completion of conventional chemotherapy and anti-CCR4 antibody for ATL acute type. The patient presented with persistent fever and monocytosis without any evidence of infectious diseases. Bone marrow examinations revealed chronic myelomonocytic leukemia-like disease with a chromosomal translocation of t(11;22)(q23;q13) as a solo cytogenetic abnormality, resulting in the diagnosis of t-MN. Next-generation sequencing analysis identified a rare chimeric transcript, MLL-EP300, without any additional somatic mutations. Although the patient underwent allogenic hematopoietic stem cell transplantation, she died of viral encephalomyelitis at 7 months after diagnosis of t-MN. Since recent therapeutic advances have extended the survival of patients with ATL, further evaluation of the long-term risks of developing t-MN in these patients is warranted.